HOOK(Delisted)
ยทNASDAQ
--
--(--)
HOOK Profile
Hookipa Pharma Inc.
A company that develops a new class of immunotherapies based on its proprietary arenavirus platform
350 Fifth Avenue, 72nd Floor, Suite 7240, New York, New York 10118
--
HOOKIPA Pharma Inc., incorporated in February 2017 under the laws of the State of Delaware in the name of Hookipa Biotech, Inc., is a wholly-owned subsidiary of Hookipa Biotech AG. The company is a clinical-stage biopharmaceutical company developing novel immunotherapies based on a proprietary arenavirus platform designed to target and amplify T-cell immune responses to fight disease. The company is building a proprietary immuno-oncology pipeline by targeting oncovirus cancer antigens, autoantigens and next-generation antigens. The company's oncology portfolio includes three disclosed programs, HB-200, HB-300 and HB-700, all of which use replication technology.
